SCHEMBL17069768

SCHEMBL17069768

Cc1noc(-c2cccc(F)c2C(=O)C(C)(C)C)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 7/20 0.52
HCRTR2 O43614 6/20 0.52
PDK2 Q15119 2/20 0.45
KMT2A Q03164 2/20 0.44
HDAC6 Q9UBN7 2/20 0.42
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC9 Q9UKV0 1/20 0.42
HDAC5 Q9UQL6 1/20 0.42
NPC1 O15118 7/20 0.42
RAB9A P51151 7/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
GAA P10253 1/20 0.42
MAOA P21397 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17071971 0.85 HCRTR1 (0.54) HCRTR1HCRTR2PDK2KMT2AHDAC6
SCHEMBL1586661 0.85 HCRTR1 (0.54) HCRTR1HCRTR2PDK2KMT2AHDAC6
SCHEMBL18594655 0.82 HCRTR1 (0.52) HCRTR1HCRTR2PDK2KMT2AHDAC6
SCHEMBL1586690 0.82 NPC1 (0.54) HCRTR1HCRTR2PDK2KMT2AHDAC6
SCHEMBL18160584 0.80 HCRTR1 (0.51) HCRTR1HCRTR2PDK2HDAC6HDAC3
SCHEMBL17448830 0.79 KMT2A (0.52) HCRTR1HCRTR2PDK2KMT2ANPC1
SCHEMBL17069772 0.79 PDK2 (0.45) HCRTR1HCRTR2PDK2KMT2AHDAC6
SCHEMBL18196000 0.76 PDK2 (0.47) HCRTR1HCRTR2PDK2KMT2AHDAC6
SCHEMBL16067350 0.75 NPC1 (0.51) HCRTR1HCRTR2PDK2KMT2AHDAC6
SCHEMBL10094742 0.75 NPC1 (0.68) PDK2KMT2AHDAC6NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975876-B2 2-pyridyloxy-3-ester-4-ether orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2018-05-22 US disclosed
US-9975876-B2 2-pyridyloxy-3-ester-4-ether orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2018-05-22 US disclosed
US-9586950-B2 2-pyridyloxy-3-ester-4-nitrile orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2017-03-07 US disclosed
US-9586950-B2 2-pyridyloxy-3-ester-4-nitrile orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2017-03-07 US disclosed
US-20160304490-A1 2-PYRIDYLOXY-3-ESTER-4-ETHER OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-10-20 US disclosed
US-20150252033-A1 2-PYRIDYLOXY-3-ESTER-4-NITRILE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2015-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252033-A1 2-PYRIDYLOXY-3-ESTER-4-NITRILE OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NTSR2 HCRTR1 2/4885HCRTR2 1/4885PDK2 1869/4885
US-20160304490-A1 2-PYRIDYLOXY-3-ESTER-4-ETHER OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY4R HCRTR1 2/4885HCRTR2 1/4885PDK2 1300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.